Key Phase 3 milestones move tofersen, eplontersen and pelacarsen closer to the market Exclusive license to Bicycle Therapeutics’ technology potentially expands LICA technology capabilities Webcast today, August 4, 2021, at 11:30 a.m. Eastern Time CARLSBAD, Calif. , Aug.
Lp(a) HORIZON achieves 50% enrollment in trial to assess the safety and efficacy of pelacarsen in reducing recurrent cardiovascular events
– Ionis-discovered pelacarsen continues to advance as potential first new therapy for Lp(a)-driven cardiovascular disease CARLSBAD, Calif. , Aug. 2, 2021 /PRNewswire/ — Ionis Pharmaceuticals, Inc. (NASDAQ: IONS) today announced that pelacarsen, formerly known as AKCEA-APO(a)-L Rx , and licensed
Ionis completes enrollment in pivotal NEURO-TTRansform study of eplontersen
– Results from interim analysis expected by mid-2022 – NDA filing to potentially follow by year-end 2022 CARLSBAD, Calif. , July 29, 2021 /PRNewswire/ — Ionis Pharmaceuticals, Inc. (NASDAQ: IONS), the leader in RNA-targeted therapies, today announced it has completed enrollment of
Biogen and Ionis report positive topline clinical data on investigational Alzheimer’s disease treatment at AAIC
– Phase 1b study of BIIB080/IONIS-MAPT Rx met primary objective of safety and tolerability – Study demonstrated durable, robust, time and dose dependent lowering of tau protein in cerebrospinal fluid CAMBRIDGE, Mass. and CARLSBAD, Calif. , July 26, 2021 /PRNewswire/ — Biogen Inc.